FDA Approves First Branded Bevacizumab for Wet AMD

The U.S. Food and Drug Administration (FDA) approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD) on Friday. Outlook Therapeutics announced the approval of bevacizumab-vikg, marketed as Lytenava, for this indication. This marks a significant step as it is the first branded bevacizumab product to receive FDA approval for wet AMD.

Previously, bevacizumab was available primarily as a compounded drug, often referred to as "off-label" use for wet AMD, despite its widespread use in ophthalmology. The approval of Lytenava provides a standardized, FDA-approved option for physicians and patients. The drug is administered via intravitreal injection, a common method for delivering treatments directly into the eye.

Outlook Therapeutics stated that Lytenava is intended to be used as an intravitreal injection to treat adult patients with wet AMD. The company has been working towards this approval for several years, conducting clinical trials to demonstrate the safety and efficacy of Lytenava for this specific condition. The approval is based on data from these trials, which showed positive outcomes in patients receiving the treatment.

The availability of an FDA-approved branded bevacizumab is expected to enhance treatment consistency and potentially streamline the regulatory and reimbursement processes for healthcare providers. This development offers a new therapeutic avenue for individuals suffering from wet AMD, a leading cause of vision loss in older adults.